CorFlow Therapeutics AG, a medical device technology company developing a novel diagnostic and drug delivery technology platform, has secured €44 Million ($48.6m) in Series B funding round to advance an innovative platform for microvascular obstruction (MVO) for patients suffering heart attacks.
Led by Paul Mead, Oliver Bludau, Sabrina Frey, and Sara Specchia, the company has developed CoFl system designed to Identify microvascular obstruction in patients suffering from heart attacks.
The system is designed to provide timely, precise, and reliable detection of MVO while patients are still in the catheter lab immediately after reopening larger epicardial arteries.
CorFlow’s latest round was spearheaded by Panakes Partners and Broadview Ventures, backed by other investors 415 Capital, Merieux Equity Partners, Wellington Partners, Laerdal Million Lives Fund, M&L Investments, KOFA Healthcare, Monte Carlo Capital, and Unorthodox Ventures.
The new capital will support the company’s MOCA II pivotal study of CoFITM System Assessment II. The study, which will run in Europe and the US, aims to validate the effectiveness of the CoFITM System in detecting MVO in heart attack patients after stent implantation.
Part of the funds will also fund a study on an adaptive platform therapy to assess the treatment effects of medications delivered into the patient’s body through the CoFl system to treat MVO.
